Clinical Research Directory
Browse clinical research sites, groups, and studies.
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
Sponsor: Reunion Neuroscience Inc
Summary
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
Official title: A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Generalized Anxiety Disorder
Key Details
Gender
All
Age Range
18 Years - 74 Years
Study Type
INTERVENTIONAL
Enrollment
64
Start Date
2026-04-20
Completion Date
2027-04
Last Updated
2026-05-18
Healthy Volunteers
No
Conditions
Interventions
RE104 for Injection
Single, subcutaneous dose of RE104 for Injection
Placebo
Single, subcutaneous dose of 0.9% sodium chloride for injection
Locations (12)
Lighthouse Psychiatry
Gilbert, Arizona, United States
Open Mind Therapeutics
San Francisco, California, United States
TRIP Clinic at Psychedelic Science Institute
Santa Monica, California, United States
University of South Florida
Tampa, Florida, United States
Atlanta Center for Medical Research
Atlanta, Georgia, United States
CenExel iResearch, LLC
Decatur, Georgia, United States
UNM Research Program Psychedelic Therapies
Albuquerque, New Mexico, United States
Summit Headlands LLC
Portland, Oregon, United States
Austin Clinical Trial Partners
Austin, Texas, United States
Aim Trials, LLC
Plano, Texas, United States
Cedar Clinical Research
Draper, Utah, United States
Inner Space State Street
Orem, Utah, United States